VEGF-A (Isoform 189) Human Protein

CAT#: AR31182PU-S

VEGF-A (Isoform 189) human recombinant protein, 2 µg

Size: 2 ug 5 ug

USD 175.00

2 Weeks*

    • 2 ug

Product Images

Other products for "VEGFA"


Product Data
Species Human
Expression Host E. coli
Expression cDNA Clone or AA Sequence
Predicted MW ~42 kDa
Purity >98% by SDS-PAGE and Silver staining
Presentation Purified
Buffer Presentation State: Purified
State: Lyophilized protein
Buffer System: 50 mM Acetic Acid
Stabilizer: None
Bioactivity Biological: Measured in a cell proliferation assay using primary human umbilical vein endothelial cells (HUVEC) and primary human dermal lymphatic endothelial cells (HDLEC). The ED50 for this effect is typically 2-10 ng/ml.
Endotoxin Endotoxin level < 0.1ng per μg of Human VEGF189
Reconstitution Restore in water to a concentration not lower than 50 μg/ml. For long term storage we recommend to add at least 0.1% Human or Bovine Serum Albumin.
Preparation Lyophilized protein
Applications Can be used as standard in a Sandwich ELISA.
Protein Description Recombinant Human Vascular Endothelial Growth Factor 189. 
Result by N-terminal sequencing: APMAEGG
Storage Store lyophilized at 2-8°C for 6 months or at -20°C long term.
After reconstitution store the antibody undiluted at 2-8°C for one month 
or (in aliquots) at -20°C long term.
Avoid repeated freezing and thawing.
Stability Shelf life: one year from despatch.
Reference Data
RefSeq NP_001020537
Locus ID 7422
UniProt ID P15692
Cytogenetics 6p21.1
Synonyms MVCD1; VEGF; VPF
Summary This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site. The levels of VEGF are increased during infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), thus promoting inflammation by facilitating recruitment of inflammatory cells, and by increasing the level of angiopoietin II (Ang II), one of two products of the SARS-CoV-2 binding target, angiotensin-converting enzyme 2 (ACE2). In turn, Ang II facilitates the elevation of VEGF, thus forming a vicious cycle in the release of inflammatory cytokines. [provided by RefSeq, Jun 2020]
Protein Families Druggable Genome, Secreted Protein
Protein Pathways Bladder cancer, Cytokine-cytokine receptor interaction, Focal adhesion, mTOR signaling pathway, Pancreatic cancer, Pathways in cancer, Renal cell carcinoma, VEGF signaling pathway

{0} Product Review(s)

0 Product Review(s) Submit review

Be the first one to submit a review

Product Citations

*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.